TraMetinib - CAS# 871700-17-3 60201 reduces sickling and prolongs RBC

reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease

CAS Number: 1410880-22-6

6 nM) and led to their apoptotic cell death

is an activator of Akt that blocks its membrane translocation while allowing its phosphorylation

Matsushita H

TraMetinib - CAS# 871700-17-3 60201 reduces sickling and prolongs RBCTrametinib, also known as GSK1120212, CAS No. 871700 17 3, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in